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DX-8951f (exatecan mesylate), a new water-soluble derivative of camptothecin, is currently being evaluated in phase II clinical
trials. Resistance may be acquired when treating cancer patients with DX-8951f. Therefore, we selected a subline of the
human ovarian cancer cell line A2780 for resistance against DX-8951f to investigate possible mechanisms of resistance. This
DX-8951f-resistant subline, designated 2780DX8 (resistance factor=9.3), displayed a typical cross-resistance pattern including
compounds, such as topotecan (resistance factor =34), SN-38 (resistance factor =47), mitoxantrone (resistance factor =59)
and doxorubicin (resistance factor =2.9), which have previously been associated with the expression of breast cancer
resistance protein. 2780DX8 cells did not show changes in the topoisomerase I gene, in topoisomerase I protein levels or
catalytic activity. Overexpression of breast cancer resistance protein could be detected, both at the mRNA and protein level,
while staining for Pgp, MRP1, or LRP was negative. GF120918, an inhibitor of breast cancer resistance protein, was able to
reverse the DX-8951f-induced resistance in 2780DX8 cells. In vivo experiments in well-established 2780DX8 human tumour
xenografts demonstrated that the growth inhibition induced by CPT-11 was more affected by breast cancer resistance protein
expression than that of DX-8951f. These data indicate for the ﬁrst time that DX-8951f is able to induce breast cancer
resistance protein as a mechanism of resistance. Breast cancer resistance protein, however, results in only minor reduction of
antitumour activity of DX-8951f which is an advantage over topotecan and CPT-11/SN-38.
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DX-8951f, (1S,9S)-1-amino-9-ethyl-5-ﬂuoro-2,3-dihydro-9-hydro-
xy-4-methyl-1H,1 2 H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]-
quinoline-10-13(9H,15H)-dione methanesulphonate dihydrate
(exatecan mesylate, Figure 1), is a new water-soluble derivative of
camptothecin. Its mechanism of action is through the inhibition
of topoisomerase I activity. The potency of DX-8951f in various
human malignant cell lines has been found to be six-fold and
28-fold greater than that of, respectively, SN-38 and topotecan
(Mitsui et al, 1995). In addition, DX-8951f has shown efﬁcacy in
a variety of human tumour xenografts (Kumazawa et al, 1998).
Phase II clinical trials on DX-8951f are currently in progress in
Europe, the United States and Japan.
A major obstacle to successful anticancer therapy is the presence
or development of drug resistance. Several mechanisms can confer
resistance against topoisomerase I inhibitors, including reduction
of topoisomerase I protein levels, decrease in the activity of the
enzyme or the presence of drug transporters (Pommier et al,
1999). It has been suggested that DX-8951f is less affected by
mechanisms of resistance described for other camptothecins. For
example, DX-8951f has shown signiﬁcant antitumour effects
against cell lines and xenografts, in which CPT-11 was not effective
(Takiguchi et al, 1997; Kumazawa et al, 1998). It may also over-
come Pgp-mediated multidrug resistance, as it is highly effective
against cell lines overexpressing the P170-glycoprotein transporter
both in vitro and in vivo (Mitsui et al, 1995; Kumazawa et al,
1998).
A recently discovered drug transporter that appears to be rele-
vant for camptothecin resistance is the breast cancer resistance
protein (BCRP) (Doyle et al, 1998). BCRP is also known as placen-
ta-speciﬁc ABC-transporter protein (ABCP) (Allikmets et al, 1998)
and mitoxantrone-resistance (MXR) protein (Miyake et al, 1999).
Overexpression of BCRP is characterised by a unique pattern of
resistance. While resistance is observed against mitoxantrone,
doxorubicin, and daunorubicin, cells remain sensitive to Vinca
alkaloids, paclitaxel and cisplatin (Ross et al, 1999). BCRP is also
involved in resistance against derivatives of camptothecin as cell
lines overexpressing this transporter exhibit resistance against topo-
tecan, SN-38 and 9-aminocamptothecin (Yang et al, 1995; Brangi et
al, 1999).
We here describe for the ﬁrst time that DX-8951f is able to
induce BCRP and functional protein in the human ovarian cancer
cell line A2780. The lowly resistant variant was designated
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www.bjcancer.com2780DX8. 2780DX8 cells were highly cross-resistant against mitox-
antrone, topotecan and SN-38, but not against camptothecin or
BNP1350. Resistance was not related to changes in topoisomerase
I gene, protein levels or DNA-relaxation activity. GF120918, an
efﬁcient inhibitor of BCRP (De Bruin et al, 1999), was able to
reverse the DX-8951f-induced resistance in 2780DX8 cells. Of
interest, the growth inhibition induced by CPT-11 in 2780DX8 s.c.
xenografts grown in nude mice was more affected by BCRP expres-
sion than that of DX-8951f.
MATERIALS AND METHODS
Drugs
DX-8951f (Daiichi Pharmaceutical Co., Tokyo, Japan), camptothe-
cin (Aldrich, Milwaukee, WI, USA), SN-38 (Daiichi or Aventis
Pharma, Vitry sur Seine, Cedex, France), BNP1350 (BioNumerik
Pharmaceuticals, Inc., San Antonio, TX, USA), 10,11-methylene-
dioxy-20(S)-camptothecin (provided by Dr ME Wall, Research
Triangle Institute, NC, USA) were prepared in DMSO (dimethyl-
sulphoxide; Riedel-de Hae ¨n, Seelze, Germany). Topotecan
(GlaxoSmithKline, Collegeville, UK) was diluted in water. CPT-
11 was purchased as a solution from Aventis Pharma. Doxorubicin
(Amersham Pharmacia, Roosendaal, The Netherlands) was
dissolved in water. Solutions of cisplatin, paclitaxel and etoposide
were obtained from Bristol-Myers Squibb (Woerden, The Nether-
lands), of 5-ﬂuorouracil from Roche (Mijdrecht, The
Netherlands) and of methotrexate from AHP Pharma (Hoofddorp,
The Netherlands). Mitoxantrone was purchased from Sigma (St
Louis, MO, USA) and was dissolved in PBS. GF120918, an inhibi-
tor of Pgp and BCRP (Hyaﬁl et al, 1993), was kindly provided by
Dr Ken Brouwer (GlaxoSmithKline, Research Triangle Park, NC,
USA) and dissolved in DMSO.
Drugs were further diluted in tissue culture medium when
investigated for their antiproliferative effects in vitro. The ﬁnal
concentration of DMSO in culture did not exceed 1% (v v
71)
which was non-toxic to the cells. When investigated in vivo
CPT-11 was further diluted in NaCl 0.9% and DX-8951f was
dissolved in water.
Development of 2780DX8
The DX-8951f-resistant cell line, 2780DX8, was established from
the human ovarian cancer cell line A2780 by continuously exposing
cells to stepwise increasing concentrations of DX-8951f, starting at
0.1 nM to a ﬁnal concentration of 8 nM after 7 months (approxi-
mately 30 passages). 2780DX8 was maintained in the presence of 8
nM DX-8951f. Both cell lines were grown in Dulbecco’s modiﬁed
Eagle’s medium (Gibco-BRL, Breda, The Netherlands) supplemen-
ted with 10% heat-inactivated foetal calf serum (FCS; Gibco-BRL),
50 IU ml
71 penicillin and 50 mgm l
71 streptomycin (ICN,
Zoetermeer, The Netherlands) in an incubator with a humidiﬁed
atmosphere containing 5% CO2,a t3 7 8C.
Doubling times were determined as follows. For each cell line a
standard curve was obtained by plating a range of 500 to
100000 cells per well in 12 replicate wells in a 96-well microtiter
plate. After 2 h the MTT [(3-(4,5-dimethylthiazol-2-yl)-2,6-
dimethyl-morpholino)-2,5-diphenyl-tetrazolium bromide; Sigma]
assay was performed (see next section). Mean absorbances
measured were plotted against the number of cells using regression
analysis. Simultaneously, for all cell lines various cell numbers were
plated in 12 replicate wells and grown for 24, 48, 72 and 96 h, after
which the MTT assay was performed. Mean absorbances measured
at each time-point were related to the cell number from the stan-
dard curves. Doubling times were calculated from the graph when
the cells were in exponential growth phase. For each cell line at
least nine separate doubling times were obtained and the mean
doubling time was calculated.
In vitro growth inhibition assay
Drug antiproliferative effects were determined with the MTT assay.
Brieﬂy, for A2780 and 2780DX8, respectively, 3000 and 5000 cells
per well in 100 ml medium were plated in 96-well microtiter plates
and grown for 24 h at 378C. Cells were exposed continuously to
serial dilutions of drug in a total volume of 200 ml for an addi-
tional 96 h. The medium was removed and 50 ml of the
tetrazolium salt MTT in PBS (0.4 mg ml
71) were added. The
plates were incubated for 2 h and formazan crystals were dissolved
in 200 ml of DMSO per 0.5% FCS. The absorbance was measured
at 540 nm using a Labsystems Multiscan Bichromatic plate reader
(Labsystems, Helsinki, Finland). The results were expressed as the
IC50, which is the concentration of drug inducing a 50% inhibition
of cell growth of treated cells when compared to the growth of
control cells. IC50 values were read from a graph expressing the
concentration of drug against the percentage of relative growth.
The ratio of IC50 resistant cells vs IC50 parent cells was presented
as the resistance factor (RF). For reversal of BCRP-induced resis-
tance against DX-8951f, SN-38, topotecan and mitoxantrone,
GF120918 was administered at a non-toxic concentration of
2 mM just prior to adding the serial dilutions of the drugs. All
concentrations were tested in four replicate wells and each experi-
ment was performed at least three times.
Northern blotting of BCRP
Total cellular RNA was isolated from exponentially growing cells
using TRIzol (GibcoBRL). Ten mg of total RNA were fractionated
on a 1% agarose-formaldehyde gel and subsequently transferred
to nitrocellulose Hybond-N
+ (Amersham Pharmacia). Blots were
prehybridized for 1 h at 428Ci n5 6SSC (16SSC: 150 mM sodium
chloride, 15 mM sodium citrate, pH 7.0), 56Denhardt’s solution,
0.2% SDS, 100 mgm l
71 salmon sperm DNA, and 50% deionized
formamide. Subsequently, the blots were probed using 25 ng of
the
32P-labeled BCRP/MXR/ABCP probe (Maliepaard et al, 1999)
at 428C overnight. After washing in 16SSC/0.1% SDS for 20 min
at room temperature and three times with 0.26SSC/0.1% SDS
for 10 min at 658C, blots were analysed using a phosphor imaging
system (Fujix Bas 2000; Fuji Photo Film Co. Ltd., Tokyo, Japan).
Two separate RNA isolations of each cell line were examined.
Gel electrophoresis and Western blotting
BCRP protein levels were determined using gel electrophoresis and
Western blotting. Whole cell lysates were made by lysing harvested
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Figure 1 Structural formula of DX-8951f, (1S,9S)-1-amino-9-ethyl-5-
ﬂuoro-2,3-dihydro-9-hydroxy-4-methyl-1H,1 2 H-benzo[de]pyrano[3',4':6,
7]indolizino[1,2-b]quinoline-10-13(9H,15H)-dione methanesulphonate di-
hydrate.
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1% Triton X-100 supplemented with 1 mM PMSF, leupeptin
(Sigma; 0.5 mgm l
71), and trypsin inhibitor (Sigma; 10 mgm l
71).
Proteins were separated on 10% sodium dodecyl sulphate polyacry-
lamide gels using the Bio-Rad Mini Protean II cell system (Bio-
Rad, Veenendaal, The Netherlands) and transferred to hybond
polyvinylene diﬂuoride membranes (Millipore, Bedford, MA,
USA). The blots were blocked overnight with 5% Protifar (Nutri-
cia, Zoetermeer, The Netherlands) in PBS at 48C, washed and
incubated with primary mouse monoclonal antibody (MAb)
BXP-21 (Maliepaard et al, 2001a) for 2 h at room temperature.
After washing, the blots were incubated with peroxidase-conjugated
rabbit anti-mouse immunoglobulins (1:1000; Dako, Copenhagen,
Denmark). Proteins were visualised using the ECL blotting detec-
tion reagents (Amersham Pharmacia). The expression levels were
quantiﬁed using Scion Image for Windows (Scion Corporation)
and six independent experiments were performed.
For determination of topoisomerase I protein levels nuclear
protein extracts were prepared from cell lines as follows. 1610
7
Cells were lysed in nuclear buffer (150 mM NaCl, 1 mM KH2PO4,
5m M MgCl2.6H2O, 1 mM EGTA, pH 6.4) supplemented with
0.3% Triton X-100, 0.8 mM phenylmethylsulphonyl ﬂuoride
(Merck, Amsterdam, The Netherlands) and 0.2 mM dithiotreitol
(Sigma) and kept on ice for 10 min. Cell nuclei were harvested
by centrifugation for 10 min at 1200 g (48C) and washed with
nuclear buffer. Nuclear proteins were extracted from the nuclei
by incubation with nuclear buffer containing 0.4 M NaCl for
30 min on ice. After centrifugation at maximum speed the enzyme
solution was diluted with an equal volume of 87% glycerol and
stored at 7708C for a maximum of a week. Total protein concen-
trations of the nuclear extracts were determined according to
Bradford. Proteins were separated on 7.5% sodium dodecyl
sulphate polyacrylamide gels and transferred to hybond polyviny-
lene diﬂuoride membranes. For detection of topoisomerase I a
polyclonal human antibody to human topoisomerase I (1:5000;
TopoGEN, Columbus, OH, USA) was used with Protein A/HRP
(1:10000; Amersham Pharmacia) as secondary reagent. The
expression levels were quantiﬁed using Scion Image in three inde-
pendent experiments.
Immunocytochemistry
For detection of Pgp, MRP1, LRP and BCRP by immunocytochem-
istry the following MAbs were used. Pgp was determined using the
murine MAb JSB-1 (IgG1), which recognizes an internal epitope of
Pgp. For detection of MRP1 the mouse MAb MRPm6 (IgG1) was
used. LRP expression was determined with the mouse MAb LRP-56
(IgG2b) and BCRP expression was assessed using the MAb BXP-34
(Scheffer et al, 2000). As positive controls the following cell lines
were included: 2780AD (Pgp), GLC4/ADR (MRP1), 2R120 (LRP)
and the MCF-7 MR cell line, overexpressing BCRP.
Staining for Pgp, MRP1, LRP and BCRP was performed on acet-
one-ﬁxed (10 min) cytospin preparations. Slides were preincubated
with 10% goat serum for 15 min and then incubated with primary
antibodies diluted in phosphate-buffered saline (PBS) containing
1% (w v
71) BSA for 1 h. Antibody binding was detected using
biotinylated goat anti-mouse IgG and streptavidin conjugated to
horseradish peroxidase (Zymed, San Francisco, CA, USA). Bound
peroxidase was visualised using the AEC Substrate Kit (Zymed).
Slides were counterstained with haematoxylin (Merck) and
mounted with Aquamount (BDH Laboratory Supplies, Poole,
UK). Negative control slides were treated as above, substituting
the primary antibody with a non-speciﬁc IgG control antibody
or PBS. Staining intensities were categorised as negative (7),
weakly positive (+), positive (+) or strongly positive (++). The
staining intensities for the different proteins were determined in
at least three independent experiments.
Topoisomerase I catalytic activity
Topoisomerase I activity was determined by measuring the relaxa-
tion of supercoiled pHOT1 plasmid DNA (TopoGEN) according to
Liu and Miller (1981). Serial dilutions of nuclear extract (0.16–
40 mgm l
71) were added to a reaction mixture containing super-
coiled pHOT1 plasmid and 125 mM Tris, 210 mM KCL, 25 mM
MgCl2, 1.25 mM EDTA and 75 mgm l
71 BSA at pH 7.5 and incu-
bated at 378C for 30 min. The reaction was stopped by adding stop
solution (30% (v v
71) glycerol 87%, 3% (w v
71) SDS, 0.3%
(w v
71) bromophenol blue). Relaxed and supercoiled DNA were
separated on a 1% agarose gel by electrophoresis and visualised
by ethidium bromide staining. One unit of topoisomerase I activity
was deﬁned as the complete relaxation of 1 mg of supercoiled
pHOT1 plasmid DNA per min at 378C. DNA topoisomerase I
activity was measured at least ﬁve times in each cell line.
Detection of topoisomerase I gene mutations
For detection of possible mutations of the topoisomerase I gene
RNA was extracted from the parental and drug-resistant cell line
using a RNeasy Mini kit (Qiagen, Valenica, CA, USA) according
to the manufacturer’s protocol. RNA was reverse transcribed using
the SuperScript preampliﬁcation system (Gibco-BRL). The three
regions A, B, and D of the topoisomerase I cDNA, already known
to bear mutations responsible for camptothecin resistance (Gupta
et al, 1995), were ampliﬁed. PCR ampliﬁcation was performed
using the PCR Reagent system (Gibco-BRL) under the following
conditions: preincubation was at 958C for 2 min followed by 30
cycles at 958C (1 min); 558C (1 min); 728C (1 min) and a ﬁnal
extension of 10 min at 728C. Cloning of the PCR fragments was
performed using the TOPO TA cloning system (Invitrogen, Carls-
bad, CA, USA). Transformation of competent cells and DNA
minipreps were performed according to standard procedures.
Sequencing was performed using the BigDye primer cycle sequen-
cing reaction kit (Applied Biosystems, Foster City, CA, USA).
Analysis of the topoisomerase I sequences was performed using
Sequencher software (Genes Code Corporation, Ann Arbor, MI,
USA) and at least six separately obtained sequences were evaluated.
In vivo antitumour efﬁcacy
For the animal experiments, ethical approval was obtained from
the ‘University Committee on Experimental Animals’. This
Committee strictly adheres to the standards required by the
UKCCCR for the welfare of animals in experimental neoplasia
(Workman et al, 1998). The xenografts were established from cell
lines grown in tissue-culture medium. Female nude mice (Hsd:
athymic nude-nu; Harlan, Horst, The Netherlands) were inoculated
subcutaneously with 1610
7 cells in both ﬂanks. Upon growth,
tumours were measured three times a week in three dimensions
with vernier calipers. The volume was calculated by the equation
length6width6thickness60.5, and expressed in mm
3. At the start
of treatment (designated as day 0), groups of ﬁve to six tumour-
bearing mice were formed to provide a mean tumour volume of
approximately 250–300 mm
3 in each group.
Doses of DX-8951f and CPT-11 for the daily 65 schedule were
administered according to the maximum tolerated dose (MTD) for
non-tumour-bearing mice. This MTD was based on the occurrence
of a mean reversible weight loss of approximately 10% of the initial
weight within the ﬁrst 2 weeks after the start of the treatment.
CPT-11 was administered i.p. at a dose of 20 mg kg
71 daily65,
as established previously (Jansen et al, 1997). According to the
MTD criteria the dose for the daily65 schedule of DX-8951f
was deﬁned as 1.5 mg kg
71 i.p.
Three evaluation criteria were used in parallel to express the
treatment efﬁcacy: (1) mean tumour growth curves; (2) speciﬁc
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day 14. The SGD was calculated by comparing the two doubling
times (T2D) of treated tumours and control tumours starting from
day 0 according to the following formula:
SGD 
T2D treated ÿ T2D control
T2D control
The RTV was calculated as the relative increase or decrease in
mean tumour volume from the start of treatment (V0) until the
value at a given time (Vt) and expressed as the mean RTV (Vt/V0).
Statistics
Differences in in vitro drug sensitivities, in vitro/in vivo growth rate,
and in vivo antitumour effects were evaluated using the two-tailed
Students’ t-test for two samples with unequal variances. Data were
normally distributed after log transformation and P-values 50.05
were considered to be signiﬁcant.
RESULTS
Growth rate and cross-resistance pattern of 2780DX8
The doubling times (+s.e.m.) of A2780 and 2780DX8 cells were
determined, showing that A2780 and 2780DX8 cells doubled in
11 h (+0.4) and 16 h (+1.0), respectively (P50.001). The DX-
8951f-resistant variant of A2780, 2780DX8, displayed a 9.3-fold
resistance against DX-8951f when compared to the parental cell
line A2780 (Table 1). 2780DX8 cells were highly cross-resistant
against the camptothecin derivatives topotecan (34-fold) and SN-
38 (47-fold) and showed a moderate resistance against 10,11-
methylenedioxy-20(S)-camptothecin (nine-fold). No cross-resis-
tance against the parent compound camptothecin, or the
camptothecin-analogue BNP1350 was observed. Evaluation of
various other drugs, including doxorubicin, cisplatin, methotrexate,
5-ﬂuoruracil, paclitaxel, etoposide and mitoxantrone, only showed
high cross-resistance against mitoxantrone (59-fold) (Table 1).
Minor cross-resistance was observed against doxorubicin (2.3-fold)
and methotrexate (3.5-fold).
Expression of Pgp, MRP1, LRP and BCRP
A2780 cells did not express any of the multidrug resistance
proteins Pgp, MRP1, LRP, and BCRP, tested (Table 2). 2780DX8
cells were negative for Pgp, MRP1 and LRP, but were strongly
positive for BCRP. Approximately 90% of the 2780DX8 cells
stained positive for BCRP. The cell lines used as a control for
expression of Pgp (2780AD), MRP1 (GLC4/ADR), LRP (2R120)
and BCRP (MCF-7 MR) indeed showed positive staining for these
proteins.
High expression of BCRP in 2780DX8 cells was conﬁrmed on
the mRNA and protein level using Northern blotting and Western
blotting. Representative experiments are shown in Figure 2A and B,
respectively. No expression of BCRP could be detected in cell
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Table 1 Antiproliferative effects of various anticancer agents against the
cell lines A2780 and 2780DX8
A2780 2780DX8
Drugs M (+s.e.m.)
b
M (+s.e.m.)
b RF
a
DX-8951f 2.8 (+0.5)610
710 2.6 (+0.4)610
79 9.3
c
Camptothecin 3.3 (+0.3)610
79 5.3 (+1.9)610
79 1.6
BNP1350 2.3 (+0.8)610
710 5.2 (+2.1)610
710 2.2
Topotecan 7.4 (+3.2)610
79 2.5 (+0.7)610
77 34
c
SN-38 5.1 (+1.7)610
79 2.4 (+0.6)610
77 47
c
MDO-CPT 3.0 (+1.3)610
710 2.7 (+0.6)610
79 9.0
c
Doxorubicin 4.2 (+0.5)610
79 9.6 (+1.5)610
79 2.3
c
Cisplatin 6.3 (+1.1)610
78 1.3 (+0.3)610
77 2.0
5-Fluoruracil 3.3 (+0.3)610
76 3.2 (+0.3)610
76 1.0
Taxol 6.2 (+2.9)610
79 3.8 (+0.5)610
79 0.6
Methotrexate 3.7 (+0.2)610
79 1.3 (+0.4)610
78 3.5
c
Etoposide 1.0 (+0.3)610
77 1.2 (+0.2)610
77 1.2
Mitoxantrone 3.4 (+1.0)610
710 2.0 (+0.4)610
78 59
c
aRF, resistance factor.
bMean IC50 in M (+s.e.m.).
cSigniﬁcantly different (P50.05)
with reference to A2780.
Table 2 Pgp, MRP1, LRP and BCRP expression in cell lines
Cell lines Pgp MRP1 LRP BCRP
A2780 7777
2780DX8 777 ++ (90%)
2780AD ++ (90%) 77 + (2%)
a
GLC4/ADR 7 ++ (95%) ++ (75%) 7
2R120 7 + (30%) ++ (75%) + (5%)
a
MCF-7 77 + /+ (5%) 7
MCF-7 MR 77 + (50%) ++ (90%)
Staining intensities expressed as strongly positive (++), positive (+), weak (+)o r
negative (7).
aNuclear staining.
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Figure 2 Northern blot of BCRP mRNA expression levels (A) and
Western blot of BCRP protein levels (B) in A2780, 2780DX8, MCF-7
and MCF-7 MR. All lanes were cut from the same Northern or Western
blot.
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levels of the protein on Western blot, but the probe used for
Northern blotting was not sensitive enough to detect BCRP
mRNA. MCF-7 MR cells, used as a positive control, showed high
expression of BCRP.
Reversal of BCRP-induced resistance
In order to determine the contribution of BCRP expression to the
resistance against DX-8951f in 2780DX8 cells, we used GF120918, a
known antagonist of BCRP function, in a series of separate experi-
ments. As can be seen in Figure 3 the resistance against DX-8951f
could be reversed to the IC50 value of the parental cell line A2780
using 2 mM GF120918. GF120918 had no effect on the sensitivity of
A2780 for DX-8951f. Of interest, the cross-resistance observed for
SN-38, topotecan and mitoxantrone, which are all highly affected
by BCRP, could also be fully reversed by GF120918.
Topoisomerase I gene, protein and activity
The amount of topoisomerase I protein in nuclear extracts from
2780DX8 cells was similar to the amount of topoisomerase I in
the parental cell line, A2780, as can be seen in a representative
experiment depicted in Figure 4. As compared to the relative inten-
sity of A2780 deﬁned as 1, the mean relative intensity (+s.e.m.) of
2780DX8 was 1.1 (+0.2). The catalytic activity of topoisomerase I
measured in both A2780 and 2780DX8 cells by ATP-independent
relaxation of supercoiled DNA demonstrated total relaxation of
the plasmid in the presence of 2.5 mgm l
71 nuclear extract. The
median activity of topoisomerase I in A2780 and 2780DX8 cells
was similar and amounted to 1.3 u mg
71 nuclear protein (range
0.7–2.7 u mg
71).
The three regions of the topoisomerase I cDNA, already known
to bear mutations responsible for camptothecin resistance (Gupta
et al, 1995; Pommier et al, 1999) were analysed for changes in
sequence when compared to the sequence found in A2780. No
mutations were detected in the domains analysed (data not
shown).
In vivo activity of CPT-11 and DX-8951f
Determination of the growth rate (+s.e.m.) of untreated tumours
revealed a slight difference in growth between A2780 and 2780DX8
xenografts as calculated starting from day 0 of the experiment.
A2780-derived tumours doubled once in volume in 2.7 (+0.2)
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Figure 3 Reversal of BCRP-induced resistance against DX-8951f, SN-38, topotecan or mitoxantrone (grey bars) using 2 mM (white bars) GF120918.
Antiproliferative effects were assessed using the MTT assay. The asterisks indicate a signiﬁcant difference with reference to 2780DX8 without
GF120918 (P50.001).
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Figure 4 Western blot of topoisomerase I protein levels from A2780
and 2780DX8 cells; 2 mg (1), 1 mg (2) and 0.5 mg (3) nuclear protein
was loaded for both cell lines.
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(+0.5) days (P50.05). The growth rate of the tumours was also
calculated from two-doubling times which was not signiﬁcantly
different between A2780 and 2780DX8 tumours. Immunohisto-
chemistry was carried out using MAb BXP-34 on tissue sections
of well-established tumours. Retention of BCRP was conﬁrmed
in 2780DX8, while no staining could be detected in A2780 xeno-
grafts (data not shown).
In the treatment experiments, drugs were given in equitoxic
schedules on the basis of a similar degree of weight loss in non-
tumour-bearing nude mice. When evaluating the weight loss
induced by both compounds in tumour-bearing mice, we observed
that DX-8951f was slightly more toxic than CPT-11. Recovery from
weight loss, however, was complete on day 14 of the experiments.
CPT-11 was hardly toxic in 2780DX8, which may be explained by
weight gain from rapid tumour growth.
Upon treatment it was clear that A2780 xenografts were more
sensitive to CPT-11 than to DX-8951f (Figure 5 and Table 3).
SGD values were 1.4 and 1.0, respectively. In contrast, the reverse
was seen in 2780DX8 xenografts in which CPT-11 was not effective
(SGD 0.1) and DX-8951f showed minor growth inhibition (SGD
0.8). The difference in efﬁcacy was conﬁrmed by the RTV values
on day 14. The RTV upon treatment with DX-8951f was 1.8-fold
higher in A2780 and 0.7-fold lower in 2780DX8 xenografts when
compared to the respective values for CPT-11.
DISCUSSION
In this report, we show for the ﬁrst time that DX-8951f is able to
induce the expression of BCRP as a mechanism of resistance, but
the compound itself is hardly affected in antitumour activity by
this transporter. The resistance against camptothecin analogues
observed in BCRP-overexpressing 2780DX8 cells could not be
related to changes in the topoisomerase I gene, in topoisomerase
I protein levels or in its catalytic activity. In addition, we excluded
the presence of other known multidrug resistance proteins. As the
resistance against camptothecins as well as mitoxantrone could be
completely reversed by GF120918, BCRP seems to be the only
resistance mechanism present. Apart from our 2780DX8 cells, a
few other cell lines have been described that show BCRP overex-
pression without change in topoisomerase I gene or protein.
Maliepaard et al (1999) have selected a topotecan-resistant variant
of the human ovarian cancer cell line IGROV-1, that overexpresses
BCRP while topoisomerase I was not affected. A CPT-11- and a
SN-38-selected subline of the lung cancer cell line PC-6, developed
by Ishii et al (2000), were found to overexpress BCRP, without any
changes in topoisomerase I. Although MRP1 levels were slightly
higher in these cell lines as compared to the protein level in paren-
tal cells, no critical role was ascribed to MRP1 because inhibition
of this transporter did not reverse resistance. It is of importance
when BCRP is present to exclude other resistance mechanisms as
the topotecan-selected human breast cancer cell line MCF-7,
described by Yang et al (2000), showed concurrent reduction of
the topoisomerase I protein content.
The difference in the degree of resistance against the various
camptothecins observed in 2780DX8 cells might give information
on the substrate afﬁnity for BCRP. 2780DX8 cells were highly resis-
tant against SN-38 and topotecan, 47- and 34-fold respectively. A
lower level of resistance was observed against DX-8951f and
10,11-methylenedioxy-20(S)-camptothecin, respectively 9.0- and
9.3-fold, while the activity of both camptothecin and BNP1350
was not changed. A similar resistance proﬁle has been described
for the other BCRP-overexpressing sublines selected for resistance
against camptothecin derivatives, in which topoisomerase I was
not affected (Ishii et al, 2000; Maliepaard et al, 2001c). We can
conﬁrm that lipophilicity of the derivatives does not seem to play
a direct role in the afﬁnity for BCRP. Although the patterns of
cross-resistance against camptothecins in BCRP-overexpressing
sublines show similarities, absolute substrate afﬁnity values should
be calculated by measuring cellular transport kinetics of the various
compounds.
Brangi et al (1999) have suggested that compounds, which are
glucuronidated in the course of their metabolism, are most likely
affected in activity in cancer cells with the BCRP phenotype.
Glucuronidation is known for SN-38 (Rivory and Robert, 1995)
as well as topotecan (Rosing et al, 1998), and both have shown
to be substrates for BCRP. There are no reasons, however, to
believe that DX-8951f will be glucuronidated. This compound
has no hydroxyl group, which is known to be easily glucuronidated
(Tephly and Burchell, 1990). Furthermore, no glucuronidated
metabolites of DX-8951f have been found until now (Dr A Tohgo,
Daiichi: personal communication). Consistent with Brangi et al
(1999), we conclude that glucuronidation is not a requirement
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also be taken into account to clarify the afﬁnity of compounds
for BCRP.
Of interest, minor cross-resistance against the antifolate metho-
trexate was observed in 2780DX8. Volk et al (2000) have recently
investigated the role of BCRP in the resistance against methotrexate
in the BCRP-overexpressing breast cancer cell line MCF7/MX,
which exhibits high cross-resistance against this drug. They
concluded that BCRP does not seem to be involved in methotrex-
ate resistance, as BCRP-transfected MCF7 cells did not display
cross-resistance, suggesting the presence of a novel MTX-speciﬁc
efﬂux pump.
Presently, not much is known about the physiological role of
BCRP. Normal tissue distribution of BCRP mRNA has demon-
strated the highest expression in placental tissue and considerably
lower expression levels are present in brain, prostate, small intes-
tine, testis, ovary, colon and liver (Doyle et al, 1998). In one
study low expression has been observed in kidney and heart as well
(Allikmets et al, 1998). Immunohistochemistry has shown that
prominent staining of BCRP is present in placental syncytiotropho-
blasts, in the epithelium of the small intestine and colon, in the
liver canalicular membrane, in ducts and lobules of the breast
and in venous and capillary, but not arterial endothelium (Malie-
paard et al, 2001a). This distribution in normal tissues resembles
the distribution of Pgp (Ambudkar et al, 1999) and may point
towards a physiological role comparable to Pgp, such as a protec-
tive function in normal tissues and fetus against toxic agents,
regulation of uptake of orally administered substrates, and excre-
tion processes in the liver.
In addition to the expression of BCRP in normal human
tissues, there is some information available on its expression in
human tumour samples. Ross et al (2000) have shown that
BCRP mRNA could be detected in blast cells obtained from
acute myeloid leukemia patients, although expression levels
varied more than 1000-fold among samples tested. Scheffer et
al (2000) have examined the protein expression of BCRP in a
panel of 57 tumour samples derived from a variety of primary
and pretreated tumours and found only one case of small-intes-
tine cancer to be weakly positive. In contrast, Izquierdo et al
(2001) have analysed 120 non-pretreated tumour samples of 20
different tumour types and detected BCRP positivity in over
40% of the samples (positive cases per tumour type 3–15).
Furthermore, Maliepaard et al (2001b) have analysed 10 samples
each of colon carcinoma, ovarian carcinoma, non-small cell lung
cancer (NSCLC) and small cell carcinomas of different origin. In
general, low staining was observed and expression was detected
in three out of 10 colon carcinomas and in six out of 10
NSCLC. It thus appears that BCRP can be present in human
tumours. Further data have to be awaited whether BCRP can
be induced as a result from treatment.
Our data suggest that the presence of BCRP in tumours
could have important consequences for the activity of several
camptothecin derivatives and future analogues. Encouraging is
the fact that, unlike topotecan and CPT-11/SN-38, DX-8951f
is only slightly affected in antitumour activity, even though
the expression of BCRP was generated by DX-8951f. In addi-
tion, the natural occurrence of BCRP in the small intestine
will limit the oral bioavailability of camptothecins that are
highly affected by this transporter. For the development of
new (oral) derivatives of camptothecin aiming at an improved
therapeutic index, it is of advantage to design molecules not
extruded by BCRP.
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